Viking Therapeutics registers two Phase 3 trials for oral VK2735 in weight management
Viking Therapeutics listed SUNRISE 1 and SUNRISE 2, twin Phase 3 studies of its oral GLP-1/GIP dual agonist VK2735, both recruiting as of their October 2026 postings.
Viking Therapeutics had two Phase 3 trials of oral VK2735 registered and recruiting during the week, both aimed at supporting a weight management indication.
- SUNRISE 2 (NCT07868939) is a Phase 3 study testing oral VK2735 in adults with Type 2 Diabetes Mellitus who are obese or overweight. The study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese or overweight adults with Type 2 Diabetes Mellitus.1 The trial plans to enroll 560 participants1 and its primary outcome is percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily over 68 weeks1. The record was first posted on 2026-10-09 and last updated on 2026-11-161.
- SUNRISE 1 (NCT07868835) is a companion Phase 3 study of oral VK2735 in adults without Type 2 Diabetes Mellitus who are obese or overweight with at least one weight-related comorbid condition. The study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese or overweight adults with at least one weight-related comorbidity without type 2 diabetes mellitus.2 It also plans to enroll 560 participants2, with eligibility requiring a BMI of 30 kg/m2 or higher, or 27 kg/m2 or higher with a weight-related comorbid condition such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease2. The record shares the same first-posted date of 2026-10-09 and last update of 2026-11-162.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.